Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Attune Pharmaceuticals Logo
Attune Pharmaceuticals Growth Score
26
CB Rank
72753
Heat Score
59
Attune Pharmaceuticals is a private biotechnology company.
Founded
obfuscation
PrivateSeries B New York, New York, United States1-10 attunepharma.com/
Biotechnology
Overview

Attune Pharmaceuticals
Total Funding
obfuscation
Growth Score
26
Heat Score
59

Total Funding
obfuscation
obfuscation
Series B raised
obfuscation
Growth Score26
-8 pts
in past quarter
Heat Score 59
-14 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Attune Pharmaceuticals

CB Rank
72753
Attune Pharmaceuticals is a private biotechnology company.
Founded
obfuscation
PrivateSeries B New York, New York, United States1-10 attunepharma.com/
Biotechnology

Funding Rounds

Series B
OBF
in
obfuscation

Key People

Details

Legal Name Attune Pharmaceuticals Inc
Operating Status Active
Company Type For Profit
Founders  Andrew McDonald
About the Company
Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel orally-administered small-molecule therapeutics for the treatment of rare diseases.
Phone Number 1-646-597-6987
Contact Email info@attunepharma.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

ATN-249
An oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE).
Complement Pathway Inhibition
A therapeutic approach targeting the complement system to treat diseases like Paroxysmal Nocturnal Hemoglobinuria (PNH).

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B
obfuscation
Series B - Attune Pharmaceuticals Logo
Series B - Attune Pharmaceuticals
6
obfuscation
Venrock Healthcare Capital PartnersSeries B

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 2 Board Members and Advisors 1

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jul 24, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 14, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Sep 10, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 15, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Active Website Tech Count

6Attune Pharmaceuticals is actively using 6 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m, Google Maps, and  Google Maps API.

Total IP

4The intellectual property of Attune Pharmaceuticals includes 4 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Attune Pharmaceuticals's headquarters? Attune Pharmaceuticals is located in New York, New York, United States.Who invested in Attune Pharmaceuticals? Attune Pharmaceuticals has 6 investors including LifeSci Venture Partners and  Boxer Capital.When was the last funding round for Attune Pharmaceuticals? Attune Pharmaceuticals closed its last funding round on
obfuscation
from a Series B round.Who are Attune Pharmaceuticals's competitors? Alternatives and possible competitors to Attune Pharmaceuticals may include Novartis, Takeda, and  BioMarin Pharmaceutical.How much funding has Attune Pharmaceuticals raised to date? Attune Pharmaceuticals has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(05b78c5 1)
|